外体载荷miR-205:眼球新血管化疗法的双重方法
Hui-Ying Zhang1,2, Qiu-Yang Zhang1,2, Qing Liu1,2
1The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, 210000, China.
Journal of nanobiotechnology
|January 23, 2025
概括
微RNA-205 (miR-205) 通过向关键生长因子,有效地抑制眼睛疾病中的病理性新血管化. 外体输送增强了对视力威胁的疾病的治疗潜力.
科学领域:
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
- 生物技术是生物技术.
背景情况:
- 病理性新血管化导致视力丧失在疾病,如湿时与年龄相关的黄斑变性.
- 目前的抗VEGF疗法存在局限性,包括对某些患者的耐药性和不足的疗效.
- 非编码RNA,如microRNA,正在成为潜在的治疗点.
研究的目的:
- 研究miR-205在病理性新血管化的作用.
- 评估miR-205作为眼部神经血管疾病的潜在治疗剂.
- 开发一个有效的传递系统miR-205使用外体.
主要方法:
- 在病理条件下评估miR-205表达水平.
- 研究了miR-205对内皮细胞功能 (增殖,迁移,管形成) 和屏障完整性的影响.
- 利用视网膜和胸腔新血管化的小鼠模型来测试miR-205的疗效.
- 采用介质干细胞衍生的外体细胞用于miR-205的输送.
主要成果:
- 在病理性新血管化中,miR-205显著下调.
- miR-205抑制了内皮细胞的增殖,迁移和管形成,并加强了内皮屏障.
- 在动物模型中,施用miR-205抑制了新血管化和血管泄漏.
- miR-205直接针对的是 VEGFA 和 ANGPT2.2.
- 外体封装的miR-205在没有细胞毒性的情况下证明了治疗效果.
结论:
- miR-205是病理性新血管化的强有力的抑制剂.
- miR-205代表了眼部神经血管疾病的有希望的治疗候选者.
- 通过外体介导的miR-205的输送为治疗危及视力的血管疾病提供了一种新有效的策略.
相关概念视频
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...